Targets › RHOA
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2027.
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organization, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. (UniProt, P61586)
Open in Phaseline: the race on RHOA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IVIEW Therapeutics | GVB-2001 Self-complementary adeno-associated viral vector (scAAV) delivering dominant-negative RhoA | RHOA | Phase 1 | Primary Open-Angle Glaucoma (POAG) | Dec 2027 |
Primary Open-Angle Glaucoma (POAG) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.